Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Suppression of allograft rejection by regulatory B cells induced via TLR signaling
Kang Mi Lee, … , Christian LeGuern, James F. Markmann
Kang Mi Lee, … , Christian LeGuern, James F. Markmann
Published August 9, 2022
Citation Information: JCI Insight. 2022;7(17):e152213. https://doi.org/10.1172/jci.insight.152213.
View: Text | PDF
Research Article Immunology Transplantation

Suppression of allograft rejection by regulatory B cells induced via TLR signaling

  • Text
  • PDF
Abstract

B lymphocytes have long been recognized for their critical contributions to adaptive immunity, providing defense against pathogens through cognate antigen presentation to T cells and Ab production. More recently appreciated is that B cells are also integral in securing self-tolerance; this has led to interest in their therapeutic application to downregulate unwanted immune responses, such as transplant rejection. In this study, we found that PMA- and ionomycin-activated mouse B cells acquire regulatory properties following stimulation through TLR4/TLR9 receptors (Bregs-TLR). Bregs-TLR efficiently inhibited T cell proliferation in vitro and prevented allograft rejection. Unlike most reported Breg activities, the inhibition of alloimmune responses by Bregs-TLR relied on the expression of TGF-β and not IL-10. In vivo, Bregs-TLR interrupted donor-specific T cell expansion and induced Tregs in a TGF-β–dependent manner. RNA-Seq analyses corroborated the involvement of TGF-β pathways in Breg-TLR function, identified potential gene pathways implicated in preventing graft rejection, and suggested targets to foster Breg regulation.

Authors

Kang Mi Lee, Qiang Fu, Guoli Huai, Kevin Deng, Ji Lei, Lisa Kojima, Divyansh Agarwal, Peter van Galen, Shoko Kimura, Naoki Tanimine, Laura Washburn, Heidi Yeh, Ali Naji, Charles G. Rickert, Christian LeGuern, James F. Markmann

×

Figure 3

Bregs-TLR confer increased graft survival.

Options: View larger image (or click on image) Download as PowerPoint
Bregs-TLR confer increased graft survival.
(A) Survival of BALB/c (H-2d)...
(A) Survival of BALB/c (H-2d) islet allografts (Kaplan-Meier plot) in μMT B6 recipient mice (H-2b) induced by adoptive transfers of various B cell subsets. Purified CD19+ B cells tested were naive B cells, Bregs-CpG, and Bregs-TLR derived from WT B6, IL-10–deficient, or TGF-β–deficient (KO) mouse strains. (B) OVA+ skin graft survival following adoptive transfer of Bregs-CpG or Bregs-TLR. Specificity controls included Bregs-TLR derived from B6 or anti-OVA transgenic BCR OBI as well as graft control B6/BM12 that expresses a transplantation antigen unrelated to OVA. P values indicate log-rank test. *P < 0.05, **P < 0.01, and ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts